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Background: The NVALT-11/DLCRG-02 phase III study compared PCI to observation
after chemo-radiotherapy (RT) for stage III NSCLC and showed a significant decrease
in the cumulative incidence of symptomatic brain metastases (BM) in the PCI arm at
two years (7% vs 27% [HR 0.23]). We here performed exploratory subgroup analyses.
Methods: Two year cumulative incidence rates were calculated and competing risk
regression, with death of any cause as competing risk, was used to examine the time to
symptomatic BM in the following subgroups: age, gender, performance status, disease
stage and tumour type, prior surgery, chemotherapy cycles, thoracic RT dose and total
concurrent chemo-RT treatment time. For continuous variables, the median was used
as a cut-off value. The effect of PCI was only examined if the initial result was
significant.
Results: In total, 174 patients were analysed. The symptomatic BM incidence was sig-
nificantly lower in the subgroup of older (>61 years) versus younger (¼<61 years)
patients (7% vs 26% [HR 0.25]). Stratified by age, PCI only significantly reduced the
symptomatic BM incidence in younger patients (9% vs 42% [HR 0.18])(Table).
Conclusions: The symptomatic BM incidence was significantly lower in older (>61
years) compared to younger (¼<61 years) patients, likely due to higher numbers of
adenocarcinoma in the younger patients group. The effect of PCI was only significant
in younger patients. This study was randomized based on treatment allocation and sub-
groups might be too small to detect significant differences. Therefore, our results are
hypothesis generating and should be prospectively tested.
Table: 86O Time to symptomatic BM per subgroup
Subgroup Hazard ratio 95% CI
Age (>61 years vs 61
years)
All 0.25 0.10 - 0.60
61 PCI vs observation 0.18 0.06 - 0.53
>61 PCI vs observation 0.47 0.09 - 2.52
Female vs Male 1.31 0.92 - 1.88
WHO performance status 0 – –
1 0.86 0.41 - 1.83
2 2.12 0.59 - 7.63
Squamous vs non-squamous 0.76 0.34 - 1.66
Stage IIIb vs IIIa 0.97 0.47 - 1.98
Prior vs no prior surgery 1.21 0.45 - 3.29
Chemotherapy cycles (>3 vs 3) 0.97 0.42 - 2.22
Thoracic RT dose (>60 Gy vs 60Gy) 1.15 0.57 - 2.36
Total concurrent chemo-RT time
(>64 days vs 64 days)
1.43 0.70 - 2.94
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Background: Immune-checkpoint inhibitors (ICIs) as second-line therapy showed an
overall survival (OS) benefit, but only 18-20% of aNSCLC patients respond with a
median progression-free survival (mPFS) of 2-4 months. The identification of bio-
markers to select patients most likely to benefit from ICIs is still an unmet need in clini-
cal practice.
Methods:We conducted a retrospective monocentric analysis in 154 aNSCLC patients
receiving single-agent nivolumab or pembrolizumab as second-line (68%) and>3rd
line (32%) therapy.We recorded complete blood cell count at baseline (T0), before
second (T1) and third cycle (T2), assessing neutrophil-lymphocyte ratio (NLR),
derived-NLR (dNLR) and lymphocyte-monocyte ratio (LMR). Statistical analyses
(univariate andmultivariate analysis) were performed to evaluate the correlation
between overall response rate (ORR), PFS and OS and the change from baseline of
NLR, dNLR and LMR at second (T0-T1) and third cycle (T0-T2). We divided bio-
marker time-series into two groups of> 30% increase and<30% increase or decrease
from baseline value.
Results: The only biomarker statistically significantly associated with survival out-
comes was NLR. An increase of> 30% of NLR from baseline to the second cycle (NLR
T0-T1) was associated with a worse PFS (3.7 vs 4.9 months, HR 1.52 95% CI 1.02 –
2.24; p¼ 0.04). We also observed a statistically significant correlation between ORR
and the>30% increase of LMR from baseline to the second (LMR T0-T1; p< 0.001)
and the third cycle (LMR T0-T2; p¼ 0.001).
Conclusions: According to the prognostic value of time-series of biomarkers at second
and third cycle from baseline, patients who experienced an increase of> 30% of NLR
after the first ICI cycle were associated with a worse PFS; also, an increase of> 30% of
LMR after the first and second ICI administration lead to a better ORR.
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Background: Patients with stage III non-small cell lung cancer (NSCLC) is a heteroge-
neous population with resectable or unresectable tumors. Current standard of care for
unresectable disease has since long been either curatively intended chemoradiotherapy
(CRT) followed by active surveillance, or palliative treatment for CRT ineligible
patients. Recently, published data have shown survival benefit of CRT followed by
immunotherapy (durvalumab). The aimwas to investigate long-term survival, treat-
ment patterns, and characteristics for unresected stage III NSCLC patients in a real-life
setting.
Methods: This nationwide study identified all stage III NSCLC patients diagnosed in
Denmark during 2006-2015 in the Danish Cancer Registry. Patient and tumor data
were linked with data on resection, CRT, radiotherapy only [RT], chemotherapy only
[CT] and comorbidity from the National Patient Registry. Survival rates were estimated
from date of diagnosis until death, migration, or end of study (2016) using Kaplan-
Meier curves.
Results:During the study period, 33,747 patients were diagnosed with NSCLC, of
which 7390 (22%) had stage III disease. Of these, 5919 (80%) patients were unresected,
and they were older (mean age 69.2 vs. 65.8 years), more frequently men (55.0% vs.
51.5%), and hadmore comorbidity (39.8% vs. 33.6%one comorbidity) compared to
the resected patients. Among the unresected patients, 40.5% received CRT, 15.1% RT,
15.6% CT, and 28.8% had no treatment. Patients receiving CRT were younger and had
less comorbidity than patients receiving RT or CT only. The 5-year overall survival rates
in the unresected group were: 10.6% CRT, 4.5% RT, and 3.6% for patients treated with
CT. Among the resected stage III NSCLC patients, 42% survived5 years.
Conclusions: The poor long-term survival rates observed among unresected stage III
NSCLC patients indicate a high unmet need for more effective therapy. New treatment
strategies, including CRT followed by immunotherapy, might improve long-term out-
comes for these patients. Increased utilization of biomarkers and correctly targeted
therapies has the potential to personalize and improve treatment of stage III NSCLC.
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Background: Approximately 30% of patients (pts) with non-small-cell lung cancer
(NSCLC) are diagnosed with locally advanced disease, which is often unresectable. The
historical standard of care (SoC) has been platinum-based chemoradiotherapy (CRT),
based on data from clinical trials conducted in selected populations. As immunother-
apy is being integrated in the treatment strategy, real-world evidence aiming at under-
standing the current management of those patients is missing.
Methods: This study is an analysis of the Epidemio-Strategy andMedical Economics
(ESME) Lung Data Platform, amulti-center real-life database using a retrospective
data collection process. This database compiles data from patient’s Electronic medical
records (EMR), inpatient hospitalisation records and Pharmacy records. 8514 pts from
20 centres with lung cancer treated between January 1st, 2015 and December 31st,
2016, were included.
Results: 822 pts with unresectable locally advanced NSCLC - 69%male, median age
65y, 61% ECOG PS0-1, 60% non-squamous histology - were included in the analysis.
Treatment was initiated in 736 pts (analysis population): 39% concurrent CRT
(cCRT), 17% sequential CRT (sCRT), 26% chemotherapy (CT) alone, 16% radiother-
apy (RT) alone and 2% other therapy. For cCRT, 95% of pts received induction chemo-
therapy before the concurrent phase, based on taxanes (32% of pts), vinorelbine (42%
of pts), or pemetrexed (16% of pts); 35% of patients received consolidation chemother-
apy. For sCRT, preferred platinum doublet chemotherapy regimens were based on tax-
anes (39% of pts), vinorelbine (26% of pts), or pemetrexed (17% of pts). Radiotherapy
was delivered to a total dose of 60-66Gy for 84% (cCRT) and 71% (sCRT). After a
median follow-up of 17months, progression rate was 62%; progression occurred in the
thorax, the brain, or at other sites in 42%, 19% and 38% of pts, respectively. Median
PFS was 8.0 months (m) for the analysis population, 9.3 m (cCRT) and 11.6 m (sCRT).
24-month OS rate was 51%, 60%, and 52%, respectively.
Conclusions: Real world data support the use of CRT in locally advanced NSCLC, with
similar outcomes than in landmark clinical trials.
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